Newsletter

Subscribe to our newsletter to stay informed.

Newsletter Overlay EN
Salutation
* Mandatory fields
Policy

Your order has been added!

Order

Publications

Number

Publication

Language

Shop EN
Greetings
*Required fields
Policy
Titelbild der Interpharma-Publikation zu seltenen Krankheiten mit Porträt eines Kleinkinds

Rare diseases – Progress in diagnosis and therapy

Although each individual rare disease is obviously a rare occurrence, a relatively large number of people are affected by rare diseases since some 8,000 of these are already known. In Switzerland, for example, this concerns some 580,000 people – the same as the number of people suffering from diabetes in this country. In addition to an interview with a doctor and a profile of a sufferer, the brochure addresses the framework conditions for the development of drugs to combat rare diseases and, taking a few examples of rare diseases such as Niemann-Pick, hairy cell leukaemia and porphyria, shows where progress has been made and where the need for further research exists. The brochure was produced in collaboration with ProRaris – the Swiss Alliance for Rare Diseases.

Order

Rare diseases – Progress in diagnosis and therapy

Add to cart

Please select the quantity

Cover of the brochure “Health Panorama 2026/2027” by Interpharma

Health Panorama 2026/2027

Key facts and figures on the Swiss health and pharmaceutical landscape: Health Panorama assesses the current developments, provides relevant data and background information and offers food for thought for the political debate.

Order

Health Panorama 2026/2027

Add to cart

Please select the quantity

Factsheet «Der Patient im Mittelpunkt» von Interpharma

Der Patient im Mittelpunkt

Der Patient im Mittelpunkt

Add to cart

Please select the quantity

First page of the Executive Insight position paper 'MFN: Looking forward'

Pharma Location Switzerland

MFN: Looking forward

MFN is already affecting Switzerland: companies are delaying or pausing launches. Low Swiss prices remain a strategic vulnerability beyond 2029, so Switzerland should prepare now.

MFN: Looking forward

Add to cart

Please select the quantity